Wolfe Research Initiates Coverage on Tempus AI (NASDAQ:TEM)

Analysts at Wolfe Research initiated coverage on shares of Tempus AI (NASDAQ:TEM) in a report released on Tuesday. The firm set a “peer perform” rating on the stock.

TEM has been the subject of a number of other research reports. Guggenheim decreased their target price on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Robert W. Baird initiated coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $80.00 price target on shares of Tempus AI in a research note on Monday. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, HC Wainwright dropped their target price on Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $68.64.

Tempus AI Stock Down 0.2%

Tempus AI stock traded down $0.08 on Tuesday, hitting $50.39. 9,705,333 shares of the stock traded hands, compared to its average volume of 6,533,951. Tempus AI has a 1 year low of $41.73 and a 1 year high of $104.32. The firm has a market cap of $9.05 billion, a P/E ratio of -30.70 and a beta of 3.64. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The business’s fifty day simple moving average is $48.81 and its 200 day simple moving average is $57.97.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company’s revenue was up 36.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.24) EPS. As a group, sell-side analysts forecast that Tempus AI will post -1.35 earnings per share for the current year.

Insider Activity

In related news, CAO Ryan M. Bartolucci sold 4,116 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the sale, the chief accounting officer directly owned 74,041 shares in the company, valued at approximately $3,262,986.87. This trade represents a 5.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 13,550 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $597,148.50. Following the completion of the transaction, the chief executive officer directly owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. This trade represents a 2.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 558,307 shares of company stock valued at $26,599,589. Corporate insiders own 24.26% of the company’s stock.

Institutional Trading of Tempus AI

A number of institutional investors have recently made changes to their positions in TEM. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the third quarter worth approximately $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI during the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI in the third quarter worth approximately $38,000. Whittier Trust Co. boosted its holdings in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC bought a new stake in Tempus AI in the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.